Title: Cardiovascular Advances in Research and Opportunities Legacy Act
Policy area: Health

Summary:
Cardiovascular Advances in Research and Opportunities Legacy Act
This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.
The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.
The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 1133 Introduced in Senate (IS)]

<DOC>






117th CONGRESS
  1st Session
                                S. 1133

    To direct the Director of the National Institutes of Health, in 
 consultation with the Director of the National Heart, Lung, and Blood 
  Institute, to establish a program to support or conduct research on 
            valvular heart disease, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             April 15, 2021

  Mr. McConnell (for himself and Ms. Sinema) introduced the following 
  bill; which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
    To direct the Director of the National Institutes of Health, in 
 consultation with the Director of the National Heart, Lung, and Blood 
  Institute, to establish a program to support or conduct research on 
            valvular heart disease, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Cardiovascular Advances in Research 
and Opportunities Legacy Act''.

SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RESEARCH.

    Subpart 2 of part C of title IV of the Public Health Service Act 
(42 U.S.C. 285b et seq.) is amended by inserting after section 424C the 
following:

``SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RESEARCH.

    ``(a) In General.--The Director of the National Institutes of 
Health, in consultation with the Director of the Institute, shall 
support or conduct research regarding valvular heart disease.
    ``(b) Support Guidelines.--The distribution of funding authorized 
in subsection (a) may be used to pursue any of the following outcomes:
            ``(1) Using precision medicine and advanced technological 
        imaging to generate data on individuals with valvular heart 
        disease.
            ``(2) Identifying and developing a cohort of individuals 
        with valvular heart disease and available data.
            ``(3) Corroborating data generated through clinical trials 
        to develop a prediction model to distinguish individuals at 
        high risk for sudden cardiac arrest or sudden cardiac death 
        from valvular heart disease.
            ``(4) Other outcomes needed to acquire necessary data on 
        valvular heart disease.
    ``(c) Mitral Valve Prolapse Workshop.--Not later than one year 
after the date of enactment of this section, the Director of the 
Institute shall convene a workshop composed of subject matter experts 
and stakeholders to identify research needs and opportunities to 
develop prescriptive guidelines for treatment of individuals with 
mitral valve prolapse.
    ``(d) Authorization of Appropriations.--For the purpose of carrying 
out this section, there is authorized to be appropriated $20,000,000 
for each of fiscal years 2022 through 2026.''.

SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL AND PREVENTION.

    Part J of title III of the Public Health Service Act (42 U.S.C. 
280b et seq.) is amended by inserting after section 393D the following 
section:

``SEC. 393E. PREVENTION OF SUDDEN CARDIAC DEATH AS A RESULT OF VALVULAR 
              HEART DISEASE.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, may carry out projects 
to increase education, awareness, or diagnosis of valvular heart 
disease and to reduce the incidence of sudden cardiac death caused by 
valvular heart disease. Such projects may be carried out by the 
Secretary directly or through awards of grants or contracts to public 
or nonprofit private entities. The Secretary may directly (or through 
such awards) provide technical assistance with respect to the planning, 
development, and operation of such projects.
    ``(b) Certain Activities.--Projects carried out under subsection 
(a) may include--
            ``(1) the implementation of public information and 
        education programs for--
                    ``(A) the prevention of sudden cardiac death from 
                valvular heart disease;
                    ``(B) broadening the awareness of the public 
                concerning the risk factors for, the symptoms of, and 
                the public health consequences of, valvular heart 
                disease; and
                    ``(C) increasing screening, detection, and 
                diagnosis of valvular heart disease; and
            ``(2) surveillance of out-of-hospital cardiac arrests to 
        improve patient outcomes.
    ``(c) Grant Prioritization.--The Secretary may, in awarding grants 
or entering into contracts pursuant to subsection (a), give priority to 
entities seeking to carry out projects that target populations most 
impacted by valvular heart disease.
    ``(d) Coordination of Activities.--The Secretary shall ensure that 
activities under this section are coordinated, as appropriate, with 
other agencies of the Public Health Service that carry out activities 
regarding valvular heart disease.
    ``(e) Best Practices.--The Secretary, acting through the Director 
of the Centers for Disease Control and Prevention, shall--
            ``(1) collect and analyze the findings of research 
        conducted with respect to valvular heart disease; and
            ``(2) taking into account such findings, publish on the 
        website of the Centers for Disease Control and Prevention best 
        practices for physicians and other health care providers who 
        provide care to individuals with valvular heart disease.
    ``(f) Authorization of Appropriations.--For the purpose of carrying 
out this section, there is authorized to be appropriated such sums as 
may be necessary for each of fiscal years 2022 through 2026.''.
                                 <all>